Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Spyre Therapeutics, Inc. (SYRE)
USD86.63
-2.26 (-2.54%)
US NASDAQ Healthcare Biotechnology
Address
221 Crescent Street 2453
Waltham, MA, US
Waltham, MA, US
CEO
Cameron Turtle
Website
spyre.com
IPO
2016-04-07
CIK 1636282 ISIN US00773J2024
Also trades on
NASDAQ Capital Market · SYRE (USD)
NASDAQ Global Market · AGLE (USD)
Description
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal antibody that aims to interact with tumor necrosis factor-like ligand 1A (TL1A). A synergistic approach is also being explored with SPY120, a compound that merges the anti-a4ß7 action of SPY001 with the anti-TL1A activity of SPY002. All these programs are currently undergoing preclinical evaluation. Beyond these, the company's early-stage portfolio encompasses several additional promising candidates: SPY003, an anti-IL-23 monoclonal antibody; SPY004, a monoclonal antibody with a novel mechanism of action; SPY130, which combines anti-a4ß7 and anti-IL-23 antibodies; and SPY230, a dual antibody therapy featuring anti-TL1A and anti-IL-23 components. Originally incorporated in 2013, the organization was previously known as Aeglea BioTherapeutics, Inc., before rebranding to Spyre Therapeutics, Inc. in November 2023. Its headquarters are located in Waltham, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD86.63
-2.26 (-2.54%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
3.06
Float Shares
52.57M
Free Float %
87.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.82% | +2.65% | +18.60% | +104.86% | +231.60% | +129.06% | +408.75% | +1,984.44% | -59.11% | -58.14% | -69.28% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (11 ratings, all time)
Buy
Price Targets & DCF
Current price
86.63
Low
49.00
-43.4%
Consensus
85.45
-1.4%
Median
90.00
+3.9%
High
107.00
+23.5%
DCF (Unlevered)
0.23
-99.7%
DCF (Levered)
0.25
-99.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 17 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 10 |
92.60
+6.9%
|
| Last Quarter | 11 |
88.64
+2.3%
|
| Last Year | 13 |
82.38
-4.9%
|
| All Time | 17 |
74.82
-13.6%
|
Quality scores
Altman Z-Score
27.86
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+37.7% ★ Q1'26: -469.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +428.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+635.8% Q1'26: +474.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 9 EPS Ana. |
Dec 2027 12 Rev. Ana. 11 EPS Ana. |
Dec 2028 9 Rev. Ana. 10 EPS Ana. |
Dec 2029 4 Rev. Ana. 4 EPS Ana. |
Dec 2030 4 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
4.63M
est: 6.91M (-33.0%)
|
5.21M
est: 4.80M (+8.4%)
|
3.89M
est: 4.57M (-14.9%)
|
—
est: 257.1K (-100.0%)
|
18.74M
est: 18.36M (+2.0%)
|
2.33M
est: 2.23M (+4.4%)
|
886.0K
est: 688.0K (+28.8%)
|
—
est: 2.61M (-100.0%)
|
—
est: 88.6K (-100.0%)
|
88.6K
88.6K – 88.6K
+0.0% YoY
|
166.7K
166.7K – 166.7K
+88.1% YoY
|
200.0K
200.0K – 200.0K
+20.0% YoY
|
50.22M
50.22M – 50.22M
+25,008.4% YoY
|
105.07M
105.07M – 105.07M
+109.2% YoY
|
| EBITDA |
-21.77M
est: -1.38M (-1,476.0%)
|
-27.43M
est: -960.2K (-2,756.4%)
|
-45.17M
est: -914.1K (-4,841.6%)
|
-77.35M
est: -51.4K (-150,310.3%)
|
-64.07M
est: -3.67M (-1,644.6%)
|
-82.82M
est: -446.1K (-18,464.7%)
|
-127.60M
est: -137.6K (-92,633.2%)
|
-207.97M
est: -522.5K (-39,702.4%)
|
-209.56M
est: -17.7K (-1,182,596.5%)
|
-17.7K
-17.7K – -17.7K
+0.0% YoY
|
-33.3K
-33.3K – -33.3K
-88.1% YoY
|
-40.0K
-40.0K – -40.0K
-20.0% YoY
|
-10.04M
-10.04M – -10.04M
-25,009.0% YoY
|
-21.01M
-21.01M – -21.01M
-109.2% YoY
|
| EBIT |
-21.91M
est: -1.38M (-1,485.6%)
|
-27.68M
est: -960.2K (-2,782.3%)
|
-45.46M
est: -914.1K (-4,873.6%)
|
-78.25M
est: -51.4K (-152,062.2%)
|
-65.65M
est: -3.67M (-1,687.5%)
|
-84.78M
est: -446.1K (-18,905.0%)
|
-128.56M
est: -137.6K (-93,333.8%)
|
-207.97M
est: -522.5K (-39,702.4%)
|
-219.56M
est: -17.7K (-1,239,033.1%)
|
-17.7K
-17.7K – -17.7K
+0.0% YoY
|
-33.3K
-33.3K – -33.3K
-88.1% YoY
|
-40.0K
-40.0K – -40.0K
-20.0% YoY
|
-10.04M
-10.04M – -10.04M
-25,009.0% YoY
|
-21.01M
-21.01M – -21.01M
-109.2% YoY
|
| Net Income |
-21.70M
est: -4.54B (+99.5%)
|
-27.24M
est: -2.25B (+98.8%)
|
-44.35M
est: -2.14B (+97.9%)
|
-78.25M
est: -2.89B (+97.3%)
|
-65.80M
est: -1.17B (+94.4%)
|
-83.82M
est: -1.27B (+93.4%)
|
-338.79M
est: -2.53B (+86.6%)
|
-208.02M
est: -1.46B (+85.8%)
|
-155.20M
est: -670.82M (+76.9%)
|
-1.03B
-1.19B – -863.30M
-53.2% YoY
|
-1.14B
-1.48B – -807.40M
-11.2% YoY
|
-1.42B
-2.00B – -844.21M
-24.3% YoY
|
-1.33B
-1.33B – -1.33B
+6.5% YoY
|
-1.37B
-1.37B – -1.37B
-2.9% YoY
|
| SGA |
8.39M
est: 83.99M (-90.0%)
|
10.07M
est: 58.37M (-82.8%)
|
12.63M
est: 55.57M (-77.3%)
|
14.83M
est: 3.13M (+374.4%)
|
27.32M
est: 223.27M (-87.8%)
|
28.53M
est: 27.12M (+5.2%)
|
39.95M
est: 8.37M (+377.5%)
|
45.78M
est: 31.76M (+44.1%)
|
47.91M
est: 1.08M (+4,347.3%)
|
1.08M
1.08M – 1.08M
+0.0% YoY
|
2.03M
2.03M – 2.03M
+88.1% YoY
|
2.43M
2.43M – 2.43M
+20.0% YoY
|
610.58M
610.58M – 610.58M
+25,008.4% YoY
|
1.28B
1.28B – 1.28B
+109.2% YoY
|
| EPS |
-55.40
est: -96.49 (+42.6%)
|
-45.01
est: -47.87 (+6.0%)
|
-53.25
est: -45.56 (-16.9%)
|
-61.23
est: -61.47 (+0.4%)
|
-25.02
est: -24.97 (-0.2%)
|
-24.86
est: -26.92 (+7.6%)
|
-46.15
est: -7.31 (-531.7%)
|
-3.18
est: -4.25 (+25.1%)
|
-1.98
est: -2.07 (+4.2%)
|
-2.87
-3.44 – -2.49
-38.9% YoY
|
-3.10
-4.27 – -2.33
-7.9% YoY
|
-3.52
-5.77 – -2.44
-13.7% YoY
|
-3.84
-3.84 – -3.84
-8.9% YoY
|
-3.95
-3.95 – -3.95
-2.9% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-06 | Citigroup | Buy | Buy | Maintain |
| 2026-04-17 | Jones Trading | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-317.75M
OE per share TTM
-2.06
Owner's Yield
-1.22%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
146.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
27
Total invested
72.55M
Insider transactions (90d)
3
Beneficial owners (>5%)
30
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Fairmount Healthcare Co-Invest LP | 19.59M | 19.99% | — | 19.59M | — | 19.59M | PN | — | 2023-06-30 | ↗ |
| 2 | Fairmount Funds Management LLC | 17.23M | 19.99% | — | 17.23M | — | 17.23M | IA | — | 2023-06-30 | ↗ |
| 3 | Peter Harwin | 17.23M | 19.99% | — | 17.23M | — | 17.23M | IN | — | 2023-06-30 | ↗ |
| 4 | Tomas Kiselak | 17.23M | 19.99% | — | 17.23M | — | 17.23M | IN | — | 2023-06-30 | ↗ |
| 5 | Fairmount Healthcare Fund II LP | 9.18M | 11.71% | — | 9.18M | — | 9.18M | PN | — | 2023-06-30 | ↗ |
| 6 | Koh, Bong | 7.98M | 9.99% | — | 7.98M | — | 7.98M | IN | United States | 2023-07-10 | ↗ |
| 7 | Shah, Nimish | 7.98M | 9.99% | — | 7.98M | — | 7.98M | IN | United States | 2023-07-10 | ↗ |
| 8 | VHCP Co-Investment Holdings III, LLC | 7.98M | 9.99% | — | 7.98M | — | 7.98M | OO | Delaware | 2023-07-10 | ↗ |
| 9 | VHCP Management EG, LLC | 7.98M | 9.99% | — | 7.98M | — | 7.98M | OO | Delaware | 2023-07-10 | ↗ |
| 10 | VHCP Management III, LLC | 7.98M | 9.99% | — | 7.98M | — | 7.98M | OO | Delaware | 2023-07-10 | ↗ |
| 11 | Venrock Healthcare Capital Partners EG, L.P. | 7.98M | 9.99% | — | 7.98M | — | 7.98M | PN | Delaware | 2023-07-10 | ↗ |
| 12 | Venrock Healthcare Capital Partners III, L.P. | 7.98M | 9.99% | — | 7.98M | — | 7.98M | PN | Delaware | 2023-07-10 | ↗ |
| 13 | Arsani William | 6.35M | 11.00% | — | 6.35M | — | 6.35M | HC, IN | United States | 2023-07-18 | ↗ |
| 14 | Logos GP LLC | 6.35M | 11.00% | — | 6.35M | — | 6.35M | OO | Delaware | 2023-07-18 | ↗ |
| 15 | Logos Global Management GP LLC | 6.35M | 11.00% | — | 6.35M | — | 6.35M | HC, OO | Delaware | 2023-07-18 | ↗ |
| 16 | Logos Global Management LP | 6.35M | 11.00% | — | 6.35M | — | 6.35M | IA, PN | Delaware | 2023-07-18 | ↗ |
| 17 | Logos Global Master Fund LP | 6.35M | 11.00% | — | 6.35M | — | 6.35M | PN | Cayman Islands | 2023-07-18 | ↗ |
| 18 | Polar Capital Funds PLC - Biotechnology Fund | 3.94M | 5.02% | 3.94M | — | 3.94M | — | OO | United Kingdom | 2023-07-28 | ↗ |
| 19 | Polar Capital Holdings Plc | 3.94M | 5.02% | 3.94M | — | 3.94M | — | HC | United Kingdom | 2023-07-28 | ↗ |
| 20 | Polar Capital LLP | 3.94M | 5.02% | 3.94M | — | 3.94M | — | IA | United Kingdom | 2023-07-28 | ↗ |
| 21 | Peter E. Deutsch | 3.55M | 6.99% | 3.55M | — | 3.55M | — | IN | United States of America | 2024-10-23 | ↗ |
| 22 | BCLS II Equity Opportunities, LP | 2.70M | 6.10% | — | 2.70M | — | 2.70M | PN | Delaware | 2020-06-09 | ↗ |
| 23 | (1) BlackRock, Inc. | 2.66M | 5.20% | 2.61M | — | 2.66M | — | HC | Delaware | 2024-11-08 | ↗ |
| 24 | Capital LP | 1.83M | 6.10% | — | 1.83M | — | 1.83M | IA | Delaware, USA | 2023-12-01 | ↗ |
| 25 | Capital Master LP | 1.83M | 6.10% | — | 1.83M | — | 1.83M | OO | Delaware, USA | 2023-12-01 | ↗ |
| 26 | Fairmount Healthcare Fund LP | 276.1K | 0.35% | — | 276.1K | — | 276.1K | PN | — | 2023-06-30 | ↗ |
| 27 | Armen B. Shanafelt, Ph.D. | 103.5K | 0.20% | 103.5K | — | 103.5K | — | IN | — | 2021-02-10 | ↗ |
| 28 | LV Management Group, LLC | — | 0.00% | — | — | — | — | OO | — | 2021-02-10 | ↗ |
| 29 | S. Edward Torres | — | 0.00% | — | — | — | — | IN | — | 2021-02-10 | ↗ |
| 30 | Steven E. Hall, Ph.D. | — | 0.00% | — | — | — | — | IN | — | 2021-02-10 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
27
-129 vs prev Q
New positions
7
Closed positions
133
Increased
16
Reduced
7
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | FMR LLC | 11.64M +2.6M (+28.5%) | 381.29M +229.4M (+151.1%) | 15.53% +3.442 pp | 0.02% +0.012 pp | USD28.11 +16.5% | 9 qtrs — |
| 2 | BLACKROCK, INC. | 5.52M +1.5M (+38.7%) | 180.90M +114.2M (+171.0%) | 7.37% +2.055 pp | 0.00% +0.002 pp | USD27.99 +17.0% | 6 qtrs — |
| 3 | RTW INVESTMENTS, LP | 4.17M +550.0K (+15.2%) | 136.67M +76.0M (+125.1%) | 5.57% +0.734 pp | 1.37% +0.621 pp | USD23.90 +37.1% | 9 qtrs — |
| 4 | VANGUARD GROUP INC | 4.04M +984.3K (+32.3%) | 132.19M +81.1M (+158.5%) | 5.39% +1.314 pp | 0.00% +0.001 pp | USD27.97 +17.1% | 10 qtrs — |
| 5 | FAIRMOUNT FUNDS MANAGEMENT LLC | 4.02M +— (+0.0%) | 131.63M +64.3M (+95.5%) | 5.36% +0.000 pp | 10.02% +3.960 pp | USD23.39 +40.1% | 10 qtrs — |
| 6 | VR ADVISER, LLC | 3.69M +1.0M (+37.2%) | 120.74M +75.7M (+168.3%) | 4.92% +1.335 pp | 5.96% +3.430 pp | USD24.99 +31.1% | 9 qtrs — |
| 7 | CAPITAL INTERNATIONAL INVESTORS | 3.49M +1.1M (+46.0%) | 114.42M +74.3M (+185.3%) | 4.66% +1.468 pp | 0.02% +0.012 pp | USD21.37 +53.3% | 4 qtrs — |
| 8 | PERCEPTIVE ADVISORS LLC | 3.07M +1.8M (+149.6%) | 100.55M +79.9M (+388.0%) | 4.10% +2.456 pp | 1.79% +1.197 pp | USD28.35 +15.6% | 10 qtrs — |
| 9 | DRIEHAUS CAPITAL MANAGEMENT LLC | 2.88M +822.0K (+39.9%) | 94.43M +59.9M (+173.5%) | 3.85% +1.097 pp | 0.64% +0.394 pp | USD24.05 +36.2% | 10 qtrs — |
| 10 | COMMODORE CAPITAL LP | 2.39M +400.2K (+20.1%) | 78.24M +44.9M (+134.8%) | 3.19% +0.534 pp | 5.21% +3.582 pp | USD23.08 +41.9% | 10 qtrs — |
| 11 | STATE STREET CORP | 2.26M +477.6K (+26.8%) | 74.13M +44.2M (+147.8%) | 3.02% +0.638 pp | 0.00% +0.001 pp | USD26.46 +23.8% | 8 qtrs — |
| 12 | TCG CROSSOVER MANAGEMENT, LLC | 1.90M +800.0K (+72.7%) | 62.26M +43.8M (+237.5%) | 2.54% +1.068 pp | 2.06% +1.153 pp | USD23.49 +39.5% | 2 qtrs — |
| 13 | TANG CAPITAL MANAGEMENT LLC | 1.89M -1.3M (-40.9%) | 61.99M +8.4M (+15.6%) | 2.53% -1.746 pp | 3.06% +0.998 pp | USD15.72 +108.4% | 4 qtrs — |
| 14 | JANUS HENDERSON GROUP PLC | 1.83M +1.8M (+13,969.3%) | 59.92M +59.7M (+27,392.4%) | 2.44% +2.424 pp | 0.03% +0.027 pp | USD32.71 +0.2% | 8 qtrs — |
| 15 | GEODE CAPITAL MANAGEMENT, LLC | 1.66M +434.0K (+35.4%) | 54.36M +33.8M (+164.7%) | 2.21% +0.579 pp | 0.00% +0.002 pp | USD27.61 +18.7% | 10 qtrs — |
| 16 | BRAIDWELL LP | 1.63M -943.8K (-36.6%) | 53.55M +10.3M (+23.9%) | 2.18% -1.260 pp | 1.71% +0.430 pp | USD23.83 +37.5% | 9 qtrs — |
| 17 | RA CAPITAL MANAGEMENT, L.P. | 1.62M +1.6M (+100.0%) | 53.12M +53.1M (+100.0%) | 2.16% +2.164 pp | 0.54% +0.544 pp | USD32.76 +0.0% | 1 qtrs NEW |
| 18 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.60M +981.3K (+158.1%) | 52.48M +42.1M (+404.5%) | 2.14% +1.310 pp | 0.01% +0.005 pp | USD27.16 +20.6% | 8 qtrs — |
| 19 | WELLINGTON MANAGEMENT GROUP LLP | 1.55M -91.0K (-5.5%) | 50.75M +23.3M (+84.6%) | 2.07% -0.122 pp | 0.01% +0.004 pp | USD24.46 +33.9% | 10 qtrs — |
| 20 | PARADIGM BIOCAPITAL ADVISORS LP | 1.47M +— (+0.0%) | 48.07M +23.5M (+95.5%) | 1.96% +0.000 pp | 1.23% +0.528 pp | USD24.92 +31.5% | 6 qtrs — |
| 21 | — | 1.46M +1.5M (+100.0%) | 47.71M +47.7M (+100.0%) | 1.94% +1.944 pp | 28.03% +28.028 pp | USD32.76 +0.0% | 1 qtrs NEW |
| 22 | AFFINITY ASSET ADVISORS, LLC | 1.43M +13.3K (+0.9%) | 46.93M +23.1M (+97.3%) | 1.91% +0.018 pp | 2.67% +0.602 pp | USD18.01 +81.9% | 10 qtrs — |
| 23 | FRANKLIN RESOURCES INC | 1.11M +314.0K (+39.5%) | 36.34M +23.0M (+172.6%) | 1.48% +0.419 pp | 0.01% +0.006 pp | USD25.40 +29.0% | 9 qtrs — |
| 24 | BAKER BROS. ADVISORS LP | 1.00M +— (+0.0%) | 32.76M +16.0M (+95.5%) | 1.33% +0.000 pp | 0.19% +0.071 pp | USD15.64 +109.5% | 3 qtrs — |
| 25 | PICTET ASSET MANAGEMENT HOLDING SA | 914.0K -122.3K (-11.8%) | 29.94M +12.6M (+72.4%) | 1.22% -0.163 pp | 0.03% +0.012 pp | USD26.08 +25.6% | 7 qtrs — |
| 26 | SIREN, L.L.C. | 818.6K +450.0K (+122.1%) | 26.82M +20.6M (+334.1%) | 1.09% +0.601 pp | 0.80% +0.558 pp | USD28.49 +15.0% | 5 qtrs — |
| 27 | POLAR CAPITAL HOLDINGS PLC | 740.3K -48.5K (-6.1%) | 24.25M +11.0M (+83.5%) | 0.99% -0.065 pp | 0.09% +0.030 pp | USD18.11 +80.9% | 10 qtrs — |
| 28 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 710.6K +97.0K (+15.8%) | 23.28M +13.0M (+126.3%) | 0.95% +0.129 pp | 0.30% +0.140 pp | USD22.66 +44.6% | 5 qtrs — |
| 29 | UBS GROUP AG | 680.6K +295.0K (+76.5%) | 22.30M +15.8M (+245.0%) | 0.91% +0.394 pp | 0.00% +0.003 pp | USD26.35 +24.3% | 9 qtrs — |
| 30 | POINT72 ASSET MANAGEMENT, L.P. | 662.4K +662.4K (+100.0%) | 21.70M +21.7M (+100.0%) | 0.88% +0.884 pp | 0.02% +0.024 pp | USD32.76 +0.0% | 1 qtrs NEW |
| 31 | EMERALD ADVISERS, LLC | 636.1K +87.4K (+15.9%) | 20.84M +11.6M (+126.6%) | 0.85% +0.117 pp | 0.64% +0.347 pp | USD27.08 +21.0% | 6 qtrs — |
| 32 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 574.6K +149.3K (+35.1%) | 18.82M +11.7M (+164.1%) | 0.77% +0.199 pp | 0.00% +0.002 pp | USD28.16 +16.3% | 8 qtrs — |
| 33 | NORTHERN TRUST CORP | 561.0K +119.0K (+26.9%) | 18.38M +11.0M (+148.1%) | 0.75% +0.159 pp | 0.00% +0.001 pp | USD28.16 +16.3% | 8 qtrs — |
| 34 | BLACKSTONE INC. | 501.0K +— (+0.0%) | 16.41M +8.0M (+95.5%) | 0.67% +0.000 pp | 0.06% +0.031 pp | USD23.18 +41.3% | 9 qtrs — |
| 35 | CANDRIAM S.C.A. | 425.5K +21.2K (+5.2%) | 13.94M +7.2M (+105.7%) | 0.57% +0.028 pp | 0.07% +0.034 pp | USD24.69 +32.7% | 8 qtrs — |
| 36 | BANK OF AMERICA CORP /DE/ | 419.7K +74.9K (+21.7%) | 13.75M +8.0M (+137.9%) | 0.56% -0.008 pp | 0.00% +0.001 pp | USD19.26 +70.1% | 8 qtrs — |
| 37 | EMERALD MUTUAL FUND ADVISERS TRUST | 412.4K +104.2K (+33.8%) | 13.51M +8.3M (+161.5%) | 0.55% +0.139 pp | 0.66% +0.391 pp | USD28.62 +14.5% | 6 qtrs — |
| 38 | CAPTION MANAGEMENT, LLC | 399.9K +314.7K (+369.4%) | 13.10M +11.7M (+817.4%) | 0.53% +0.420 pp | 0.09% +0.079 pp | USD29.04 +12.8% | 3 qtrs — |
| 39 | GOLDMAN SACHS GROUP INC | 275.1K -54.5K (-16.5%) | 9.01M +3.5M (+63.2%) | 0.37% -0.073 pp | 0.00% +0.000 pp | USD18.49 +77.2% | 8 qtrs — |
| 40 | WOODLINE PARTNERS LP | 265.9K +134.0K (+101.6%) | 8.71M +6.5M (+294.1%) | 0.35% +0.179 pp | 0.03% +0.023 pp | USD28.90 +13.4% | 8 qtrs — |
| 41 | CAPITAL WORLD INVESTORS | 200.2K +— (+0.0%) | 6.56M +3.2M (+95.5%) | 0.27% +0.000 pp | 0.00% +0.000 pp | USD23.28 +40.7% | 5 qtrs — |
| 42 | ARMISTICE CAPITAL, LLC | 196.4K +40.4K (+25.9%) | 6.43M +3.8M (+146.1%) | 0.26% +0.054 pp | 0.08% +0.038 pp | USD25.92 +26.4% | 7 qtrs — |
| 43 | BANK OF NEW YORK MELLON CORP | 192.8K +56.9K (+41.8%) | 6.32M +4.0M (+177.2%) | 0.26% +0.076 pp | 0.00% +0.001 pp | USD25.81 +26.9% | 8 qtrs — |
| 44 | HIGHVISTA STRATEGIES LLC | 188.2K -27.5K (-12.8%) | 6.17M +2.5M (+70.5%) | 0.25% -0.037 pp | 1.59% +0.702 pp | USD18.71 +75.1% | 9 qtrs — |
| 45 | SILVERARC CAPITAL MANAGEMENT, LLC | 187.7K +187.7K (+100.0%) | 6.15M +6.2M (+100.0%) | 0.25% +0.251 pp | 0.85% +0.854 pp | USD32.76 +0.0% | 1 qtrs NEW |
| 46 | MORGAN STANLEY | 182.7K -152.0K (-45.4%) | 5.99M +376.4K (+6.7%) | 0.24% -0.203 pp | 0.00% +0.000 pp | USD19.30 +69.7% | 10 qtrs — |
| 47 | BARCLAYS PLC | 182.5K +77.1K (+73.1%) | 5.98M +2.9M (+92.8%) | 0.24% +0.070 pp | 0.00% +0.001 pp | USD26.04 +25.8% | 9 qtrs — |
| 48 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 171.2K +60.8K (+55.0%) | 5.61M +3.8M (+203.0%) | 0.23% +0.081 pp | 0.01% +0.006 pp | USD26.60 +23.2% | 5 qtrs — |
| 49 | NUVEEN, LLC | 151.0K +54.8K (+57.0%) | 4.95M +3.3M (+206.9%) | 0.20% +0.073 pp | 0.00% +0.001 pp | USD22.17 +47.8% | 4 qtrs — |
| 50 | INVESCO LTD. | 150.9K +100.2K (+197.7%) | 4.94M +4.1M (+481.9%) | 0.20% +0.134 pp | 0.00% +0.001 pp | USD29.02 +12.9% | 8 qtrs — |
| 51 | PATIENT SQUARE CAPITAL LP | 150.0K +150.0K (+100.0%) | 4.91M +4.9M (+100.0%) | 0.20% +0.200 pp | 1.05% +1.052 pp | USD32.76 +0.0% | 1 qtrs NEW |
| 52 | TD ASSET MANAGEMENT INC | 149.8K +77.5K (+107.0%) | 4.91M +3.7M (+304.7%) | 0.20% +0.103 pp | 0.00% +0.003 pp | USD25.82 +26.9% | 8 qtrs — |
| 53 | VICTORY CAPITAL MANAGEMENT INC | 146.1K -180.0K (-55.2%) | 4.79M -679.6K (-12.4%) | 0.20% -0.240 pp | 0.00% -0.001 pp | USD20.88 +56.9% | 5 qtrs — |
| 54 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 129.0K +57.1K (+79.3%) | 4.14M +2.9M (+243.7%) | 0.17% +0.076 pp | 0.00% +0.002 pp | USD28.63 +14.4% | 8 qtrs — |
| 55 | PARKMAN HEALTHCARE PARTNERS LLC | 124.5K -76.3K (-38.0%) | 4.08M +713.5K (+21.2%) | 0.17% -0.102 pp | 0.39% +0.037 pp | USD16.76 +95.5% | 2 qtrs — |
| 56 | DEUTSCHE BANK AG\ | 121.9K +83.4K (+216.4%) | 3.99M +3.3M (+518.4%) | 0.16% +0.111 pp | 0.00% +0.001 pp | USD29.57 +10.8% | 8 qtrs — |
| 57 | MERCER GLOBAL ADVISORS INC /ADV | 106.3K -348.0 (-0.3%) | 3.48M +1.7M (+94.8%) | 0.14% -0.001 pp | 0.01% +0.002 pp | USD14.98 +118.7% | 3 qtrs — |
| 58 | F/M INVESTMENTS LLC | 103.7K +48.8K (+88.9%) | 3.40M +2.5M (+269.3%) | 0.14% +0.065 pp | 0.13% +0.094 pp | USD27.33 +19.9% | 5 qtrs — |
| 59 | CITIGROUP INC | 100.1K +67.2K (+204.2%) | 3.28M +2.7M (+494.5%) | 0.13% +0.090 pp | 0.00% +0.001 pp | USD29.88 +9.6% | 9 qtrs — |
| 60 | SEVEN GRAND MANAGERS, LLC | 100.0K +100.0K (+100.0%) | 3.28M +3.3M (+100.0%) | 0.13% +0.134 pp | 0.25% +0.250 pp | USD32.76 +0.0% | 1 qtrs NEW |
| 61 | B GROUP, INC. | 100.0K +— (+0.0%) | 3.28M +1.6M (+95.5%) | 0.13% +0.000 pp | 2.42% +1.186 pp | USD19.72 +66.1% | 5 qtrs — |
| 62 | SWISS NATIONAL BANK | 96.5K +26.3K (+37.5%) | 3.16M +2.0M (+168.7%) | 0.13% +0.035 pp | 0.00% +0.001 pp | USD31.75 +3.2% | 8 qtrs — |
| 63 | RHUMBLINE ADVISERS | 83.0K +12.0K (+17.0%) | 2.72M +1.5M (+128.7%) | 0.11% +0.016 pp | 0.00% +0.001 pp | USD23.88 +37.2% | 7 qtrs — |
| 64 | WELLS FARGO & COMPANY/MN | 82.4K +43.1K (+109.6%) | 2.70M +2.0M (+309.7%) | 0.11% +0.058 pp | 0.00% +0.000 pp | USD27.59 +18.7% | 10 qtrs — |
| 65 | DIMENSIONAL FUND ADVISORS LP | 77.3K -6.9K (-8.2%) | 2.53M +1.1M (+79.4%) | 0.10% -0.009 pp | 0.00% +0.000 pp | USD16.76 +95.5% | 2 qtrs — |
| 66 | MILLENNIUM MANAGEMENT LLC | 76.2K -332.0K (-81.3%) | 2.50M -4.3M (-63.5%) | 0.10% -0.443 pp | 0.00% -0.002 pp | USD16.76 +95.5% | 2 qtrs — |
| 67 | BALYASNY ASSET MANAGEMENT L.P. | 73.5K +73.5K (+100.0%) | 2.41M +2.4M (+100.0%) | 0.10% +0.098 pp | 0.00% +0.003 pp | USD32.76 +0.0% | 1 qtrs NEW |
| 68 | ALLIANCEBERNSTEIN L.P. | 67.5K +31.3K (+86.3%) | 2.21M +1.6M (+264.2%) | 0.09% +0.042 pp | 0.00% +0.001 pp | USD28.35 +15.6% | 7 qtrs — |
| 69 | ALPS ADVISORS INC | 63.7K +63.7K (+100.0%) | 2.09M +2.1M (+100.0%) | 0.09% +0.085 pp | 0.01% +0.012 pp | USD32.76 +0.0% | 1 qtrs NEW |
| 70 | JPMORGAN CHASE & CO | 63.0K -213.0K (-77.2%) | 2.06M -2.6M (-55.4%) | 0.08% -0.371 pp | 0.00% 0.000 pp | USD17.79 +84.1% | 10 qtrs — |
| 71 | UBS ASSET MANAGEMENT AMERICAS INC | 62.2K +22.7K (+57.5%) | 2.04M +1.4M (+207.9%) | 0.08% +0.030 pp | 0.00% +0.000 pp | USD24.76 +32.3% | 7 qtrs — |
| 72 | SCHRODER INVESTMENT MANAGEMENT GROUP | 61.6K -46.2K (-42.8%) | 1.96M +200.4K (+11.4%) | 0.08% -0.062 pp | 0.00% +0.000 pp | USD21.93 +49.4% | 5 qtrs — |
| 73 | LEGAL & GENERAL GROUP PLC | 56.4K +9.6K (+20.5%) | 1.85M +1.1M (+135.6%) | 0.08% +0.013 pp | 0.00% +0.000 pp | USD28.03 +16.9% | 8 qtrs — |
| 74 | RAFFERTY ASSET MANAGEMENT, LLC | 53.4K -6.3K (-10.5%) | 1.75M +749.7K (+75.0%) | 0.07% -0.008 pp | 0.01% +0.003 pp | USD23.51 +39.3% | 7 qtrs — |
| 75 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 53.1K +31.4K (+144.3%) | 1.74M +1.4M (+377.5%) | 0.07% +0.042 pp | 0.03% +0.021 pp | USD26.21 +25.0% | 2 qtrs — |
| 76 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 48.0K +14.8K (+44.7%) | 1.57M +1.0M (+182.8%) | 0.06% +0.020 pp | 0.00% +0.001 pp | USD31.93 +2.6% | 8 qtrs — |
| 77 | AMERIPRISE FINANCIAL INC | 38.3K +38.3K (+100.0%) | 1.25M +1.3M (+100.0%) | 0.05% +0.051 pp | 0.00% +0.000 pp | USD32.76 +0.0% | 1 qtrs NEW |
| 78 | METLIFE INVESTMENT MANAGEMENT, LLC | 38.0K +8.1K (+27.1%) | 1.25M +743.8K (+148.3%) | 0.05% +0.011 pp | 0.01% +0.004 pp | USD25.63 +27.8% | 7 qtrs — |
| 79 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 37.9K -30.7K (-44.8%) | 1.24M +91.5K (+8.0%) | 0.05% -0.041 pp | 0.01% -0.002 pp | USD17.13 +91.2% | 9 qtrs — |
| 80 | CINCTIVE CAPITAL MANAGEMENT LP | 35.9K +35.9K (+100.0%) | 1.18M +1.2M (+100.0%) | 0.05% +0.048 pp | 0.06% +0.064 pp | USD32.76 +0.0% | 1 qtrs NEW |
| 81 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 35.1K +8.7K (+32.9%) | 1.15M +706.5K (+159.8%) | 0.05% +0.012 pp | 0.00% +0.001 pp | USD27.34 +19.8% | 7 qtrs — |
| 82 | ADAR1 CAPITAL MANAGEMENT, LLC | 34.1K +— (+0.0%) | 1.12M +544.8K (+95.5%) | 0.05% +0.000 pp | 0.08% +0.028 pp | USD15.49 +111.5% | 9 qtrs — |
| 83 | STEMPOINT CAPITAL LP | 32.4K +32.4K (+100.0%) | 1.06M +1.1M (+100.0%) | 0.04% +0.043 pp | 0.18% +0.182 pp | USD32.76 +0.0% | 1 qtrs NEW |
| 84 | VOYA INVESTMENT MANAGEMENT LLC | 27.3K +27.3K (+100.0%) | 893.6K +893.6K (+100.0%) | 0.04% +0.036 pp | 0.00% +0.001 pp | USD32.76 +0.0% | 7 qtrs — |
| 85 | STATE OF WISCONSIN INVESTMENT BOARD | 27.3K -6.3K (-18.8%) | 892.8K +330.5K (+58.8%) | 0.04% -0.008 pp | 0.00% +0.001 pp | USD28.77 +13.9% | 8 qtrs — |
| 86 | WAVERLY ADVISORS, LLC | 26.0K +1.0 (+0.0%) | 850.3K +415.3K (+95.5%) | 0.03% +0.000 pp | 0.01% +0.003 pp | USD16.29 +101.1% | 4 qtrs — |
| 87 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | 25.8K +— (+0.0%) | 845.0K +413.0K (+95.6%) | 0.03% +0.000 pp | 0.01% +0.003 pp | USD28.31 +15.7% | 6 qtrs — |
| 88 | OPTIMIZE FINANCIAL INC | 25.3K +364.0 (+1.5%) | 829.8K +411.4K (+98.3%) | 0.03% +0.001 pp | 0.42% +0.200 pp | USD16.99 +92.8% | 2 qtrs — |
| 89 | VIRGINIA RETIREMENT SYSTEMS ET AL | 25.0K +6.5K (+34.9%) | 817.4K +507.3K (+163.6%) | 0.03% +0.009 pp | 0.00% +0.003 pp | USD20.90 +56.7% | 2 qtrs — |
| 90 | CITADEL ADVISORS LLC | 24.9K +24.9K (+100.0%) | 815.7K +815.7K (+100.0%) | 0.03% +0.033 pp | 0.00% +0.000 pp | USD32.76 +0.0% | 1 qtrs NEW |
| 91 | SG AMERICAS SECURITIES, LLC | 23.3K +23.3K (+100.0%) | 765.0K +765.0K (+100.0%) | 0.03% +0.031 pp | 0.00% +0.001 pp | USD32.76 +0.0% | 1 qtrs NEW |
| 92 | ASSENAGON ASSET MANAGEMENT S.A. | 22.1K +— (+0.0%) | 725.2K +354.2K (+95.5%) | 0.03% +0.000 pp | 0.00% +0.001 pp | USD29.37 +11.5% | 8 qtrs — |
| 93 | PROFUND ADVISORS LLC | 20.6K +7.4K (+55.7%) | 674.6K +453.0K (+204.4%) | 0.03% +0.010 pp | 0.02% +0.013 pp | USD26.89 +21.8% | 7 qtrs — |
| 94 | NEW YORK STATE COMMON RETIREMENT FUND | 19.2K +2.6K (+15.7%) | 627.8K +350.2K (+126.1%) | 0.03% +0.004 pp | 0.00% +0.001 pp | USD28.98 +13.0% | 9 qtrs — |
| 95 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 18.4K +4.6K (+33.0%) | 601.5K +370.0K (+159.9%) | 0.02% +0.006 pp | 0.01% +0.003 pp | USD23.03 +42.2% | 5 qtrs — |
| 96 | INTECH INVESTMENT MANAGEMENT LLC | 18.3K -2.1K (-10.2%) | 598.7K +257.4K (+75.4%) | 0.02% -0.003 pp | 0.01% +0.002 pp | USD22.00 +48.9% | 6 qtrs — |
| 97 | NEO IVY CAPITAL MANAGEMENT | 18.3K +18.3K (+100.0%) | 598.2K +598.2K (+100.0%) | 0.02% +0.024 pp | 0.09% +0.095 pp | USD32.76 +0.0% | 1 qtrs NEW |
| 98 | GLOBAL ENDOWMENT MANAGEMENT, LP | 18.2K +— (+0.0%) | 596.0K +291.2K (+95.6%) | 0.02% +0.000 pp | 0.07% +0.036 pp | USD21.52 +52.2% | 9 qtrs — |
| 99 | AQR CAPITAL MANAGEMENT LLC | 17.8K +773.0 (+4.5%) | 583.8K +298.1K (+104.3%) | 0.02% +0.001 pp | 0.00% +0.000 pp | USD15.74 +108.1% | 3 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.17
Bearish
Ratio by volume
0.44
Bearish
Buys
4
Sells
23
Shares acquired
106.3K
Shares disposed
242.6K
Cash buys
—
Cash sales
19.00
Net activity
-136,291
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-01 | Turtle Cameron | Director / Officer | S-Sale | D | Common Stock | 300 | 74.96 | 22.5K | 612,540 | D | ↗ |
| 2026-05-01 | Sloan Sheldon | Officer | S-Sale | D | Common Stock | 10,358 | 73.74 | 763.8K | 5,459 | D | ↗ |
| 2026-05-01 | Burrows Scott L | Officer | M-Exempt | D | Stock Option (Right to Buy) | 12,500 | 14.50 | 181.3K | 382,357 | D | ↗ |
| 2026-04-01 | Turtle Cameron | Director / Officer | S-Sale | D | Common Stock | 2,656 | 49.92 | 132.6K | 627,540 | D | ↗ |
| 2026-04-01 | Sloan Sheldon | Officer | S-Sale | D | Common Stock | 7,958 | 50.00 | 397.9K | 0 | D | ↗ |
| 2026-04-01 | Burrows Scott L | Officer | S-Sale | D | Common Stock | 1,300 | 49.98 | 65.0K | 97,994 | D | ↗ |
| 2026-03-03 | Burrows Scott L | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,500 | 14.50 | 36.3K | 402,357 | D | ↗ |
| 2026-03-02 | Turtle Cameron | Director / Officer | S-Sale | D | Common Stock | 9,100 | 42.49 | 386.7K | 642,540 | D | ↗ |
| 2026-02-02 | Turtle Cameron | Director / Officer | S-Sale | D | Common Stock | 957 | 31.82 | 30.5K | 671,583 | D | ↗ |
| 2026-01-21 | HENDERSON MICHAEL THOMAS | Director | J-Other | A | Common Stock | 63,227 | 0.00 | — | 168,606 | D | ↗ |
| 2026-01-09 | Turtle Cameron | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 528,000 | 30.61 | 16.16M | 528,000 | D | ↗ |
| 2026-01-09 | Sloan Sheldon | Officer | A-Award | A | Stock Option (Right to Buy) | 140,000 | 30.61 | 4.29M | 140,000 | D | ↗ |
| 2026-01-09 | King-Jones Heidy | Officer | A-Award | A | Stock Option (Right to Buy) | 140,000 | 30.61 | 4.29M | 140,000 | D | ↗ |
| 2026-01-09 | Burrows Scott L | Officer | A-Award | A | Stock Option (Right to Buy) | 140,000 | 30.61 | 4.29M | 140,000 | D | ↗ |
| 2026-01-02 | Turtle Cameron | Director / Officer | S-Sale | D | Common Stock | 12,709 | 30.47 | 387.2K | 674,198 | D | ↗ |
| 2025-12-01 | Turtle Cameron | Director / Officer | S-Sale | D | Common Stock | 10,995 | 28.73 | 315.9K | 690,912 | D | ↗ |
| 2025-11-03 | Turtle Cameron | Director / Officer | S-Sale | D | Common Stock | 28,155 | 23.13 | 651.2K | 718,752 | D | ↗ |
| 2025-09-02 | Burrows Scott L | Officer | S-Sale | D | Common Stock | 18,428 | 16.26 | 299.6K | 97,994 | D | ↗ |
| 2025-05-29 | Stelzer Laurie | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 15.55 | 388.8K | 25,000 | D | ↗ |
| 2025-05-29 | Milligan Sandra | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 15.55 | 388.8K | 25,000 | D | ↗ |
| 2025-05-29 | McKenna Mark C. | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 15.55 | 388.8K | 25,000 | D | ↗ |
| 2025-05-29 | HENDERSON MICHAEL THOMAS | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 15.55 | 388.8K | 25,000 | D | ↗ |
| 2025-05-29 | Fairmount Funds Management LLC | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 15.55 | 388.8K | 25,000 | I | ↗ |
| 2025-05-29 | Albers Jeffrey W. | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 15.55 | 388.8K | 25,000 | D | ↗ |
| 2025-01-15 | Turtle Cameron | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 370,000 | 21.66 | 8.01M | 370,000 | D | ↗ |
| 2025-01-15 | Sloan Sheldon | Officer | A-Award | A | Stock Option (Right to Buy) | 95,500 | 21.66 | 2.07M | 95,500 | D | ↗ |
| 2025-01-15 | King-Jones Heidy | Officer | A-Award | A | Stock Option (Right to Buy) | 95,500 | 21.66 | 2.07M | 95,500 | D | ↗ |
| 2025-01-15 | Burrows Scott L | Officer | A-Award | A | Stock Option (Right to Buy) | 95,500 | 21.66 | 2.07M | 95,500 | D | ↗ |
| 2025-01-10 | HENDERSON MICHAEL THOMAS | Director | J-Other | A | Common Stock | 105,379 | 0.00 | — | 105,379 | D | ↗ |
| 2024-11-06 | Albers Jeffrey W. | Director | S-Sale | D | Common Stock | 6,700 | 36.76 | 246.3K | 27,360 | I | ↗ |
| 2024-10-25 | Albers Jeffrey W. | Director | S-Sale | D | Common Stock | 300 | 36.43 | 10.9K | 34,060 | I | ↗ |
| 2024-10-01 | Sloan Sheldon | Officer | A-Award | A | Stock Option (Right to Buy) | 400,000 | 27.46 | 10.98M | 400,000 | D | ↗ |
| 2024-09-03 | Burrows Scott L | Officer | S-Sale | D | Common Stock | 18,531 | 28.17 | 522.1K | 116,422 | — | ↗ |
| 2024-05-14 | Stelzer Laurie | Director | A-Award | A | Stock Option (Right to Buy) | 11,323 | 39.29 | 444.9K | 11,323 | — | ↗ |
| 2024-05-14 | Milligan Sandra | Director | A-Award | A | Stock Option (Right to Buy) | 21,980 | 39.29 | 863.6K | 21,980 | — | ↗ |
| 2024-05-14 | HENDERSON MICHAEL THOMAS | Director | A-Award | A | Stock Option (Right to Buy) | 11,323 | 39.29 | 444.9K | 11,323 | — | ↗ |
| 2024-05-14 | Fairmount Funds Management LLC | Director | A-Award | A | Stock Option (Right to Buy) | 11,323 | 39.29 | 444.9K | 11,323 | — | ↗ |
| 2024-05-14 | Albers Jeffrey W. | Director | A-Award | A | Stock Option (Right to Buy) | 11,323 | 39.29 | 444.9K | 11,323 | — | ↗ |
| 2024-04-25 | Fairmount Funds Management LLC | Director | M-Exempt | D | Series A Preferred Stock | 90,992 | 0.00 | — | 346,045 | — | ↗ |
| 2024-02-15 | Turtle Cameron | Director / Officer | A-Award | A | Common Stock | 400 | 9.82 | 3.9K | 746,907 | — | ↗ |
| 2024-02-01 | Turtle Cameron | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 277,750 | 25.86 | 7.18M | 277,750 | — | ↗ |
| 2024-02-01 | McKenna Mark C. | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 25.86 | 1.03M | 40,000 | — | ↗ |
| 2024-02-01 | King-Jones Heidy | Officer | A-Award | A | Stock Option (Right to Buy) | 63,000 | 25.86 | 1.63M | 63,000 | — | ↗ |
| 2024-02-01 | Burrows Scott L | Officer | A-Award | A | Stock Option (Right to Buy) | 70,000 | 25.86 | 1.81M | 70,000 | — | ↗ |
| 2023-12-29 | Fairmount Funds Management LLC | Director / 10% Owner | J-Other | A | Common Stock | 406,038 | 0.00 | — | 406,038 | — | ↗ |
| 2023-12-07 | Fairmount Funds Management LLC | Director / 10% Owner | A-Award | A | Series B Preferred Stock | 16,667 | 0.00 | — | 16,667 | — | ↗ |
| 2023-11-24 | Albers Jeffrey W. | Director | C-Conversion | A | Common Stock | 34,360 | 0.00 | — | 34,360 | I | ↗ |
| 2023-11-22 | Albers Jeffrey W. | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 10.39 | 519.5K | 50,000 | D | ↗ |
Executive team
Top executives
Shares Outstanding
60.40M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Cameron Turtle Chief Executive Officer | 665.0K | — | — | 5.55M | 475.5K | 14.0K | 6.71M | 82.79% | ↗ |
| 2 | 2025 | Sheldon Sloan Chief Medical Officer | 503.0K | — | — | 1.43M | 261.6K | 14.0K | 2.21M | 64.80% | ↗ |
| 3 | 2025 | Heidy King-Jones Chief Legal Officer and Corporate Secretary | 490.0K | — | — | 1.43M | 254.8K | 14.0K | 2.19M | 65.38% | ↗ |
| 4 | 2025 | Scott Burrows Chief Financial Officer | 490.0K | — | — | 1.43M | 254.8K | 14.0K | 2.19M | 65.38% | ↗ |
| 5 | 2024 | Sheldon Sloan Chief Medical Officer | 124.0K | 120.0K | — | 9.08M | 59.5K | 9.8K | 9.39M | 96.66% | ↗ |
| 6 | 2024 | Cameron Turtle Chief Executive Officer | 625.0K | — | — | 5.91M | 412.5K | 8.3K | 6.96M | 84.97% | ↗ |
| 7 | 2024 | Scott Burrows Chief Financial Officer | 475.0K | — | — | 1.49M | 228.0K | 13.8K | 2.21M | 67.53% | ↗ |
| 8 | 2024 | Heidy King-Jones Chief Legal Officer and Corporate Secretary | 480.0K | — | — | 1.34M | 230.4K | — | 2.05M | 65.38% | ↗ |
| 9 | 2023 | Cameron Turtle Chief Executive Officer | 272.9K | 141.0K | — | 15.50M | — | 5.2K | 15.92M | 97.37% | ↗ |
| 10 | 2023 | Jonathan Alspaugh Former Chief Financial Officer | 329.8K | 735.6K | — | 7.06M | — | 234.7K | 8.36M | 84.45% | ↗ |
| 11 | 2023 | Scott Burrows Chief Financial Officer | 154.6K | 175.7K | 2.45M | 4.77M | — | 1.5K | 7.55M | 95.61% | ↗ |
| 12 | 2023 | Heidy King-Jones Chief Legal Officer and Corporate Secretary | 168.7K | 62.7K | — | 6.36M | — | — | 6.59M | 96.49% | ↗ |
| 13 | 2023 | Jeffrey M. Goldberg Former President and Chief Executive Officer | 248.5K | — | — | — | — | 581.7K | 830.2K | 0.00% | ↗ |
| 14 | 2022 | Anthony G. Quinn, M.B Ch.B, Ph.D. Former President and Chief Executive Officer | 424.4K | — | — | 779.6K | — | 1.19M | 2.39M | 32.59% | ↗ |
| 15 | 2022 | Jeffrey M. Goldberg President and Chief Executive Officer | 54.6K | — | — | 1.77M | — | 2.9K | 1.83M | 96.86% | ↗ |
| 16 | 2022 | Jeffrey M. Goldberg Former President and Chief Executive Officer | 54.6K | — | — | 1.77M | — | 2.9K | 1.83M | 96.86% | ↗ |
| 17 | 2022 | Leslie Sloan, Ph.D. Former Chief Operating Officer | 435.0K | — | — | 465.6K | 174.0K | 13.3K | 1.09M | 42.80% | ↗ |
| 18 | 2022 | Jonathan Alspaugh Chief Financial Officer | 425.0K | — | — | 443.3K | 130.6K | 13.0K | 1.01M | 43.81% | ↗ |
| 19 | 2022 | Jonathan Alspaugh Former Chief Financial Officer | 425.0K | — | — | 443.3K | 130.6K | 13.0K | 1.01M | 43.81% | ↗ |
| 20 | 2022 | Jim Kastenmayer General Counsel, Corporate Secretary and Former Interim Chief Executive Officer | 443.9K | — | — | 253.9K | 155.7K | 12.2K | 865.8K | 29.33% | ↗ |
| 21 | 2022 | Jim Kastenmayer Former General Counsel, Corporate Secretary and Interim Chief Executive Officer | 443.9K | — | — | 253.9K | 155.7K | 12.2K | 865.8K | 29.33% | ↗ |
| 22 | 2021 | Anthony G. Quinn, M.B Ch.B, Ph.D. Chief Executive Officer | 560.0K | — | 1.70M | — | 332.0K | 29.7K | 2.62M | 64.86% | ↗ |
| 23 | 2021 | Anthony G. Quinn, M.B Ch.B, Ph.D. Former President and Chief Executive Officer | 560.0K | — | — | 1.70M | 332.0K | 29.7K | 2.62M | 64.86% | ↗ |
| 24 | 2021 | Leslie Sloan, Ph.D. Chief Operating Officer | 410.0K | — | 822.5K | — | 200.0K | 16.9K | 1.45M | 56.75% | ↗ |
| 25 | 2021 | Leslie Sloan, Ph.D. Former Chief Operating Officer | 410.0K | — | — | 822.5K | 200.0K | 16.9K | 1.45M | 56.75% | ↗ |
| 26 | 2021 | Michael Hanely Chief Operating Officer | 380.0K | — | 704.7K | — | 180.0K | 17.4K | 1.28M | 54.96% | ↗ |
| 27 | 2020 | Anthony G. Quinn, M.B Ch.B, Ph.D. Chief Executive Officer | 538.0K | — | 2.09M | — | 256.0K | 25.7K | 2.91M | 71.83% | ↗ |
| 28 | 2020 | Charles N. York II Former Chief Financial Officer and Vice President | 415.0K | — | 860.4K | — | — | 8.1K | 1.28M | 67.04% | ↗ |
| 29 | 2020 | Leslie Sloan, Ph.D. Chief Operating Officer | 370.0K | — | 708.0K | — | 148.0K | 20.3K | 1.25M | 56.80% | ↗ |
| 30 | 2019 | Anthony G. Quinn, M.B Ch.B, Ph.D. Chief Executive Officer | 518.0K | — | 1.66M | — | 247.0K | 53.9K | 2.48M | 67.02% | ↗ |
| 31 | 2019 | Leslie Sloan, Ph.D. Chief Operating Officer | 355.0K | — | 632.4K | — | 142.0K | 19.8K | 1.15M | 55.03% | ↗ |
| 32 | 2019 | Charles N. York II Chief Financial Officer and Vice President | 390.0K | — | 522.4K | — | 165.0K | 7.7K | 1.09M | 48.14% | ↗ |
| 33 | 2019 | Charles N. York II Former Chief Financial Officer and Vice President | 390.0K | — | 522.4K | — | 165.0K | 7.7K | 1.09M | 48.14% | ↗ |
| 34 | 2018 | Anthony G. Quinn, M.B Ch.B, Ph.D. Chief Executive Officer | 507.0K | — | 2.92M | — | 304.0K | 111.6K | 3.84M | 75.99% | ↗ |
| 35 | 2018 | Charles N. York II Chief Financial Officer and Vice President | 343.0K | — | 424.8K | — | 185.0K | 8.0K | 960.8K | 44.22% | ↗ |
| 36 | 2018 | James Wooldridge, M.D. Chief Medical Officer | 380.0K | 135.0K | 209.3K | — | — | 19.8K | 744.0K | 28.13% | ↗ |
| 37 | 2017 | David G. Lowe, Ph.D. Former Chief Executive Officer | 278.1K | — | 936.3K | — | — | 228.8K | 1.44M | 64.88% | ↗ |
| 38 | 2017 | Charles N. York II Chief Financial Officer and Vice President | 325.0K | 130.0K | 660.1K | — | — | 15.7K | 1.13M | 58.37% | ↗ |
| 39 | 2017 | Anthony G. Quinn, M.B Ch.B, Ph.D. Chief Executive Officer | 295.3K | 150.0K | 544.6K | — | — | 37.8K | 1.03M | 52.99% | ↗ |
| 40 | 2017 | Anthony G. Quinn, M.B Ch.B, Ph.D. Interim Chief Executive Officer | 295.3K | 150.0K | 544.6K | — | — | 37.8K | 1.03M | 52.99% | ↗ |
| 41 | 2017 | Anthony G. Quinn, M.B Ch.B, Ph.D. President and Chief Executive Officer | 295.3K | 150.0K | 544.6K | — | — | 37.8K | 1.03M | 52.99% | ↗ |
| 42 | 2017 | James Wooldridge, M.D. Chief Medical Officer | 162.9K | 59.0K | 393.4K | — | — | 317.3K | 932.6K | 42.18% | ↗ |
| 43 | 2016 | David G. Lowe, Ph.D. President and Chief Executive Officer | 431.9K | 163.6K | 852.8K | — | — | 15.1K | 1.46M | 58.28% | ↗ |
| 44 | 2016 | David G. Lowe, Ph.D. Former Chief Executive Officer | 431.9K | 163.6K | 852.8K | — | — | 15.1K | 1.46M | 58.28% | ↗ |
| 45 | 2016 | Charles N. York II Chief Financial Officer and Vice President | 299.7K | 78.0K | 301.0K | — | — | 7.5K | 686.3K | 43.86% | ↗ |
| 46 | 2016 | Scott W. Rowlinson, Ph.D. Vice President, Research | 271.8K | 61.0K | 258.1K | — | — | 16.6K | 607.5K | 42.48% | ↗ |
| 47 | 2015 | David G. Lowe, Ph.D. President and Chief Executive Officer | 382.5K | 66.9K | 522.0K | — | — | 14.3K | 985.7K | 52.96% | ↗ |
| 48 | 2015 | Scott W. Rowlinson, Ph.D. Vice President, Research | 249.5K | 49.8K | 118.8K | — | — | 14.9K | 433.0K | 27.44% | ↗ |
| 49 | 2015 | Charles N. York II Chief Financial Officer and Vice President | 233.2K | 61.2K | 95.0K | — | — | 5.3K | 394.7K | 24.08% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Cameron Turtle DPHIL | Chief Executive Officer & Director | 1M | — |
| Sheldon Sloan | Chief Medical Officer | 778.6K | — |
| Heidy Abreu King-Jones | Chief Legal Officer & Corporate Secretary | 758.8K | female |
| Scott L. Burrows | Chief Financial Officer | 758.8K | male |
| Justin LaFountaine | Senior Vice President of Corporate Development | — | — |
| Melissa Cooper | Senior Vice President of People | — | female |
| Janet Gunzner-Toste | Senior Vice President of Operations | — | — |
| Eric McIntyre | Vice President of Finance & Investor Relations | — | male |
| James Myers | Vice President of Quality & Compliance | — | male |
| Brian Connolly | Chief Technical Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SYRE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
